Human papillomavirus and cervical cytology in adolescents

Adolescent Medicine Clinics

Volumn 15, Issue 2, 2004, Pages 301-321

  Kahn, Jessica A ^a   Hillard, Paula A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONDYLOMA; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; INFECTION RISK; REVIEW; RISK ASSESSMENT; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VAGINA DISEASE; VERRUCA VULGARIS; VIRAL GENETICS; VIRUS CLASSIFICATION; WART VIRUS;

ADOLESCENT; CERVIX UTERI; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES; UTERINE CERVICAL DYSPLASIA;

EID: 3142572611     PISSN: 15473368     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.admecli.2004.03.001     Document Type: Review

References (124)

1. Severson JL, Beutner KR, Tyring SK. Genital papillomavirus infection. In: Stanberry LR, Bernstein DI, editors. Sexually transmitted diseases: vaccines, prevention and control. London: Academic Press; 2000. p. 259-72.
2. Turek LP, Smith EM. The genetic program of genital human papillomaviruses in infection and cancer. Obstet Gynecol Clin North Am 1996;23(4):735-57.
3. Turek LP. The structure, function, and regulation of papillomaviral genes in infection and cervical cancer. Adv Virus Res 1994;44:305-56.
4. deVilliers EM. Human papillomavirus: introduction. Semin Cancer Biol 1999;9:377.
5. Association of Reproductive Health Care Professionals. Human papillomavirus (HPV) and cervical cancer [serial online]. Clinical Proceedings. March 2001. Available at: http://www.arhp.org/healthcareproviders/ onlinepublications/clinicalproceedings/cphpv/contents.cfm?ID=92. Accessed on March 30, 2004.
6. de Villiers EM. Taxonomic classification of papillomaviruses. Papillomavirus Rep 2001;12:57-63.
7. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
10. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-63.
11. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102(5A):3-8.
12. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57.
13. Fisher M, Rosenfeld W, Burk R. Cervicovaginal human papillomavirus infection in surburban adolescents and young adults. J Pediatr 1991;119:821-5.
14. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
15. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157(3):218-26.
16. Kahn JA, Slap GB, Huang B, Rosenthal SL, Wanchick AM, Kollar LM, et al. Comparison of adolescent self-collected and clinician-collected samples for human papillomavirus. Obstetrics and Gynecology, in press.
17. Solomon D, Davey D, Kurman R, Moriaty A, O'Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
18. Moscicki AB. Human papillomavirus infection in adolescents. Pediatr Clin North Am 1999; 46(4):783-807.
19. Sadeghi S, Hsieh E, Gunn S. Prevalence of cervical intraepithelial neoplasia in sexually active teenagers and young adults. Results of data anaylsis of mass Papanicolaou screening of 796,337 women in the United States in 1981. Am J Obstet Gynecol 1984;148:726-9.
20. Mangan SA, Legano LA, Rosen CM, McHugh MT, Fierman AH, Dreyer BP, et al. Increased prevalence of abnormal Papanicolaou smears in urban adolescents. Arch Pediatr Adolesc Med 1997;151:481-4.
21. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 1999;103:539-45.
22. Edelman M, Fox AS, Alderman EM, Neal W, Shapiro A, Silver EJ, et al. Cervical Papanicolaou smear abnormalities in inner city Bronx adolescents: prevalence, progression, and immune modifiers. Cancer 1999;87:184-9.
23. Kahn JA, Goodman E, Slap GB, Huang B, Emans SJ. Intention to return for Pap smears in adolescent and young adult women. Pediatrics 2001;108:333-41.
24. Tjiong MY, Out TA, Ter Schegget J, Burger MPM, Van Der Vange N. Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical carcinoma in the lower female genital tract: a review. Int J Gynecol Cancer 2001;11:9-17.
25. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277-84.
26. Moscicki AB, Hills NK, Shiboski S, Powell K, Jy N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
27. Wallin K, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type-specificpersistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341(22):1633-8.
28. Kjaer SK, van den Brule AJ, Gerson P, Svare EI, Sherman ME, Thomsen BL, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intrapithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572-8.
29. Moscicki AB, Hills NK, Shiboski S. High rate of regression of low-grade squamous intraepithelial lesions in adolescents. Presented at the Pediatric Academic Societies Annual Meeting. Baltimore, MD, May 4, 2002.
30. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67(5):665-9.
31. Nash JD, Burke TW, Hoskins WJ. Biologic course of cervical human papillomavirus infection. Obstet Gynecol 1987;69(2):160-2.
32. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al, editors. SEER Cancer Statistics Review, 1973-1999. Bethesda (MD): National Cancer Institute; 2002. Available at: http://seer.cancer.gove/csr/1973_1999/. Accessed April 2004.
33. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human Papillomavirus infection in young women. J Infect Dis 1996;174:679-89.
34. Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997;6(10):799-805.
35. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002;29(11):725-35.
36. Ozsaran AA, Ates T, Dikmen Y, Zeytinoglu A, Terek C, Erhan Y, et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papillomavirus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999;20:127-30.
37. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and highrisk HIV-negative women. J Natl Cancer Inst 1999;91(3):226-36.
38. Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM, Burk RD, et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J Acquir Immune Defic Syndr 1999;21(1):33-41.
39. Harrison HR, Phil D, Costin M, Meder JB, Bownds LM, Sim DA, et al. Cervical chlamydia trachomatis infection in university women: relationship to history, contraception, ectopy, and cervicitis. Am J Obstet Gynecol 1985;153(3):244-51.
40. Guijon FB, Paraskevas M, Brunham R. The association of sexually transmitted diseases with cervical intraepithelial neoplasia: a case-control study. Am J Obstet Gynecol 1985;151(2):185-90.
41. Moscicki AB, Winkler B, Irwin C, Schachter J. Differences in biologic maturation, sexual behavior, and sexually transmitted disease between adolescents with and without cervical intraepithelial neoplasia. J Pediatr 1989;115:487-93.
42. Johnson BA, Poses RM, Fortner CA, Meier FA, Dalton HP. Derivation and validation of a clinical diagnostic model for chlamydial cervical infection in university women. JAMA 1990;264(24):3161-5.
43. Moss GB, Clemetson D, D'Costa L, Plummer FA, Ndinya-Achola JO, Reilly M, et al. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis 1991;164(3):588-91.
44. Moscicki AB, Burt VG, Kanowitz S, Darragh T, Shiboski S. The significance of squamous metaplasia in the development of low grade squamous intraepithelial lesions in young women. Cancer 1999;85:1139-44.
45. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002;35(Suppl 2):S210-24.
46. Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. Clin Infect Dis 1998;27(4):796-806.
47. Beutner K, Wiley D, Douglas J, Tyring S. Genital warts and their treatment. Clin Infect Dis 1998;28:S37-56.
48. Wilson JD, Brown CB, Walker PP. Factors involved in clearance of genital warts. Int J STD AIDS 2001;12(12):789-92.
49. Campion MJ, Greenberg MD, Kazamel TIG. Clinical manifestations and natural history of genital human papillomavirus infections. Obstet Gynecol Clin North Am 1996;23(4):783-809.
50. Stafford EM, Greenberg H, Miles PA. Cervical intraepithelial neoplasia III in an adolescent with Bowenoid papulosis. J Adolesc Health Care 1990;11(6):523-6.
51. De Silva AH, Sivapalan S, Harindra V, Roy RB. Emerging incidence of vulval intraepithelial neoplasia in young women with genital warts. Genitourin Med 1992;68(5):346-7.
52. Cardosi RJ, Bomalaski JJ, Hoffman MS. Diagnosis and management of vulvar and vaginal intraepithelial neoplasia. Obstet Gynecol Clin North Am 2001;28(4):685-702.
53. Dodge JA, Eltabbakh GH, Mount SL, Walker RP, Morgan A. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol 2001;83(2):363-9.
54. Koss LG. The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989;261(5):737-43.
55. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9.
56. Kahn JA, Chiou V, Allen JD, Goodman E, Perlman SE, Emans SJ. Beliefs about Papanicolaou smears and compliance with Papanicolaou smear follow-up in adolescents. Arch Pediatr Adolesc Med 1999;153(10):1046-54.
57. Serlin M, Shafer MA, Tebb K, Gyamfi AA, Moncada J, Schachter J, et al. What sexually transmitted disease screening method does the adolescent prefer? Adolescents' attitudes toward first-void urine, self-collected vaginal swab, and pelvic examination. Arch Pediatr Adolesc Med 2002;156(6):588-91.
58. Lavin C, Goodman E, Perlman S, Kelly LS, Emans SJ. Follow-up of abnormal Papanicolaou smears in a hospital-based adolescent clinic. J Pediatr Adolesc Gynecol 1997;10:141-5.
59. Kahn JA, Goodman E, Huang B, Slap GB, Emans SJ. Predictors of Papanicolaou smear return in a hospital-based adolescent and young adult clinic. Obstet Gynecol 2003;101:490-9.
60. Igra V, Millstein SG. Current status and approaches to improving preventive services for adolescents. JAMA 1993;269(11):1408-12.
61. Wilcox LS, Mosher WD. Factors associated with obtaining health screening among women of reproductive age. Public Health Rep 1993;108:76-86.
62. Kahn JA, Colditz GA, Aweh GN, Frazier AL. Prevalence and correlates of pelvic examinations in sexually active female adolescents. Ambul Pediatr 2002;2:212-7.
63. Linder J, Zahniser D. The ThinPrep Pap test. A review of clinical studies. Acta Cytol 1997;41:30-8.
64. Linder J. Recent advances in thin-layer cytology. Diagn Cytopathol 1998;18(1):24-32.
65. Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Bratti MC, et al. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 1999;87(2):48-55.
66. Coste J, Cochand-Priollet B, De Cremoux P, Le Gales C, Cartier I, Molinie V, et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ 2003;326:733-7.
67. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
68. Saslow D, Runowicz C, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
69. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 1999;281:347-53.
70. De Sutter P, Coibion M, Vosse M, Hertens D, Huet F, Wesling F, et al. A multicentre study comparing cervicography and cytology in the detection of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 1998;105:613-20.
71. Schneider DL, Herrero R, Bratti C, Greenberg MD, Hildesheim A, Sherman ME, et al. Cervicography screening for cervical cancer among 8460 women in a high-risk population. Am J Obstet Gynecol 1999;180:290-8.
72. Moscicki AB, Durako SJ, Ma Y, Darragh T, Vermund SH. Utility of cervicography in HIVinfected and uninfected adolescents. J Adolesc Health 2003;32(3):204-13.
73. Lorincz AT. Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin North Am 1996;23(3):707-30.
74. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36(10):3020-7.
75. Fait G, Daniel Y, Kupferminc MJ, Lessing JB, Niv J, Bar-Am A. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities? Gynecol Oncol 1998;70:319-22.
76. Manos MM, Kinney WK, Hurley LB, Sherman ME, Sheih-Hgai J, Kurman RJ, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-10.
77. Schneider A, Zahm DM, Kirchmayr R, Schneider VL. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. Am J Obstet Gynecol 1996;174:1534-41.
78. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high-risk types as a triage before colposcopy. Am J Obstet Gynecol 1995;172:1150-7.
79. Cox JT. Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings. JAMA 1999;281(17):1645-7.
80. Nobbenhuis MA,Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervicalcancer screening: a prospective study. Lancet 1999;354:20-5.
81. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188(6):1383-92.
82. Ferris DG, Wright TC, Litaker MS, Richart RM, Lorinez AT, Sun XW, et al. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? J Fam Pract 1998;46:125-34.
83. Bergeron C, Jeannel D, Poveda JD, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000;95:821-7.
84. Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS. High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age. J Reprod Med 2000;45(4):345-50.
85. Shlay JC, Dunn T, Byers T, Baron AE, Douglas Jr JM. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears. Obstet Gynecol 2000;96(3):410-6.
86. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patientswith atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93(4):293-9.
87. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
88. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287(18):2382-90.
89. Wright TC, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6.
90. Petry KU, Bohmer G, Iftner T, Flemming P, Stoll M, Schmidt RE. Human papillomavirus testing in primary screening for cervical cancer of human immunodeficiency virus-infected women, 1990-1998. Gynecol Oncol 1999;75:427-31.
91. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, et al. HPV testing in primary screening of older women. Br J Cancer 1999;81:554-8.
92. Guido R, Schiffman M, Solomon D, Burke L. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003;188(6):1401-5.
93. Hillemanns P, Kimmig R, Huttemann U, Dannecker C, Thaler CJ. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet 1999;354(9194):1970.
94. Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;163(5):513-8.
95. Harper DM, Noll WW, Belloni DR, Cole BF. Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed - biologic condordance and women's preferences. Am J Obstet Gynecol 2002;186:365-73.
96. American College of Obstetricians and Gynecologists. Practice Bulletin No ACOG 45. Cervical cytology screening. Obstet Gynecol 2003;102:417-27.
97. Centers for Disease Control and Prevention. CDC guideline for immunocompromised women; USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep 1995;44(RR-8):1-34.
98. Hillard PJA, Biro FM, Wildey LS, Bradley JM, Burket RL, Rauh JL. The value of an adolescent dysplasia clinic. Adolesc Pediatr Gynecol 1989;2:43-6.
99. Hillard PA, Biro FM, Wildey L. Complications of cervical cryotherapy in adolescents. J Reprod Med 1991;36(10):711-6.
100. Wright Jr TC, Cox JT, Massad LS, Carlson J, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol 2003;189(1):295-304.
101. Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for tretament of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998;92:737-44.
102. Wilson J. Treatment of genital warts - what's the evidence? Int J STD AIDS 2002;13(4):216-20.
103. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002;51(RR-6):53-7.
104. Beutner KR, Conant MA, Friedman-Kien AE, Illeman M, Artman NN, Thisted RA, et al. Patient-applied podofilox for treatment of genital warts. Lancet 1989;1:831-4.
105. Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick Jr RK. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991;77(5):735-9.
106. Beutner KR, Wiley DJ. Recurrent external genital warts: a literature review. Papillomavirus Rep 1997;8:69-74.
107. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178(2):551-5.
108. Tyring S, Conant M, Marini M, Van Der Meijden W, Washenik K. Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol 2002;41(11):810-6.
109. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Arch Dermatol 1998;134(1):25-30.
110. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas Jr JM. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38(2 Pt 1):230-9.
111. Edwards L. Imiquimod in clinical practice. J Am Acad Dermatol 2000;43(1 Pt 2):S12-7.
112. Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol 2001;137(3):337-41.
113. Owens ML, Bridson WE, Smith SL, Myers JA, Fox TL, Wells TM. Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts. Prim Care Update Ob Gyns 1998;5(4):151.
114. Filiberti A, Tamburini M, Stefanon B, Merola M, Bandieramonte G, Ventafridda V, et al. Psychological aspects of genital human papillomavirus infection: a preliminary report. J Psychosom Obstet Gynaecol 1993;14(2):145-52.
115. Persson G, Dahlof LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 1993;20(1):10-3.
116. Chandler MG. Genital warts: a study of patient anxiety and information needs. Br J Nurs 1996;5(3):174-9.
117. Clarke P, Ebel C, Catotti DN, Stewart S. The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996;7(3):197-200.
118. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000;96:653-6.
119. Gerhardt CA, Pong K, Kollar LM, Hillard PJ, Rosenthal SL. Adolescents' knowledge of human papillomavirus and cervical dysplasia. J Pediatr Adolesc Gynecol 2000;13(1):15-20.
120. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001;93:284-92.
121. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
122. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis 2000;27:49-52.
123. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gen Based Med 2000;9:47-50.
124. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003;14(5):300-6.